The finding that rheumatoid arthritis (RA) patients often produce antibodies against citrullinated peptides and proteins was a major advance both in understanding the mechanisms that trigger the disease and in its early diagnosis. Citrulline is a “nonstandard” amino acid that forms in the inflammatory environment as a result of the action of the enzyme peptidiliargininine deaminase on arginine residues present in proteins. Anti-citrullinated peptides are produced locally in the synovium of RA patients. The introduction of new immunoassays based on specially selected cyclic citrullinated peptides (CCP), allowed the development of tests with sensitivity equal to or better than traditional rheumatoid factor (RF), but with a much higher specificity. In addition to this, it was demonstrated that the presence of anti-CCP is both an early marker of AR (anti-CCP can be found up to 10 years before the onset of symptoms) and a marker of the severity of the disease. DIESSE is offering the new second generation anti-CCP Chorus kit to complete its line of tests for the serological diagnosis of systemic inflammatory diseases, in the convenient and pratical single determination format.
Read more

The Early Embryo Viability Assessment (Eeva) test is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy. Eeva uses intelligent computer vision software to measure key scientifically and clinically validated cell-division parameters from video images. It predicts with high accuracy at the cleavage stage which embryos will likely grow to the blastocyst stage, a critical milestone in embryo development. Until now, the field of reproductive medicine has been using subjective observation to determine embryo viability. With the commercial launch of Eeva, IVF clinics and their patients will now have access to a noninvasive test that delivers consistent, objective and actionable information to help identify viable embryos and determine which ones offer the greatest potential for transfer. The safety and efficacy of Eeva were validated in a prospective, multi-centre, 160-patient clinical trial, results of which were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey. In the study, Eeva was able to predict blastocyst formation at the cleavage stage with 85% specificity, reducing the false positive rate from 43% to 15% compared with traditional morphology selection. Eeva also demonstrated the ability to track and analyse cell division timings with greater than 90% accuracy. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. Eeva provides early results that allow for timely decision-making. During the IVF cycle, there is a checkpoint on Day 3 in which clinicians make decisions about whether to transfer embryos. Eeva provides information about embryo viability as early as Day 3, allowing clinicians to select a viable embryo in a timely manner, thereby increasing the likelihood of a successful patient outcome. Eeva consists of the Eeva Dish, which contains microwells enabling the tracking of the individual development of each embryo and allowing embryos to grow under group culture technique; the Eeva Scope that fits into most standard IVF incubators and provides automatic dark-field image capture and cell-division tracking without intervention by the embryologist or excessive light exposure to the embryos; the Eeva Scope Screen that fits on the outside of the incubator and allows the embryologist to control each patient session and view the latest images without opening the incubator or disturbing the embryos; the Eeva Station where images and videos for each Eeva patient session can be easily reviewed. The downloadable reports and videos may aid when counseling patients and improve the overall patient experience. Eeva is currently approved and available for use in the EU with the first installation at the Hewitt Fertility Centre in Liverpool.  

Read more

This compact 30 test/hour analyser is designed for daily use in labs with low throughput and offers all the qualities of a 60 test/hour instrument at an aff ordable cost. The COUNTENDER 30 features 20 parameters, 3 histograms and excellent CVs. It outclasses most 60 tests/hour analysers in terms of performance and quality of results and is top of its category, providing results in under 2mins. It also features very low reagent consumption. Combining simplified maintenance and long shelf-life of the company’s reagents (up to 36 months), the blood cell counter has low servicing requirements and enables signifi cant cost per test reduction for labs.
Read more

Rapid, simultaneous detection of respiratory pathogens

The Respiratory Multiplex Array is intended for the simultaneous detection of 22 bacterial and viral respiratory pathogens in individuals suspected of Respiratory Tract Infections.  The ability to simultaneously detect these in one sample provides clinicians with a complete patient profile, enabling faster and more appropriate treatment decisions. 

The Respiratory Multiplex Array is based on a combination of multiplex PCR, biochip hybridization and chemiluminescence detection using the Evidence Investigator analyser.  The array can run 54 samples simultaneously in five hours.  Identifying multiple pathogens will provide a rapid and more cost-effective diagnostic tool than current methods – which only look for single pathogens – thus reducing the time from presentation to treatment and minimizing sample requirements.   Save time and costs associated with single pathogen detection by using the Respiratory Multiplex Array.

Website:             http://www.randox.com/respiratory-molecular-test.php

Email:                 marketing@randox.com
Read more